Evidence map›Paper›PMID 33476387›Full record

ArticleThe Journal of infectious diseases2021

Immune Profiling to Determine Early Disease Trajectories Associated With Coronavirus Disease 2019 Mortality Rate: A Substudy from the ACTT-1 Trial.

Joshua M Thiede, Abigail R Gress, Samuel D Libby, Christine E Ronayne, William E Matchett, Brooke Noren, Joanne L Billings, Vineet D Menachery, Ryan A Langlois, Susan Kline and 1 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Remdesivir: treatment of COVID-19 in special populations.Naunyn-Schmiedeberg's archives of pharmacology · 2024
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Joshua M ThiedeDepartment of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
Abigail R GressDepartment of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
Samuel D LibbyDepartment of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
Christine E RonayneDepartment of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
William E MatchettCenter for Immunology, University of Minnesota, Minneapolis, Minnesota, USA.
Brooke NorenDivision of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
Joanne L BillingsDivision of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
Vineet D MenacheryDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
Ryan A LangloisCenter for Immunology, University of Minnesota, Minneapolis, Minnesota, USA.
Susan KlineDepartment of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
Tyler D BoldDepartment of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
University of Minnesota · USThe University of Texas Medical Branch at Galveston · US

Funding

Infectious Disease Training in Clinical InvestigationT32AI055433 · NIAID · UNIVERSITY OF MINNESOTA TWIN CITIES · PI David R Boulware · 2003 to 2026
$6.1M
Identifying host and viral correlates for coronavirus pathogenesisR01AI153602 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI JOHNSON, BRYAN A · 2020 to 2023
$2.0M
NIAID NIH HHS R01 AI153602NIAID NIH HHS T32 AI055433
6 · The paper itself

Abstract

Coronavirus disease 2019 (COVID-19) outcomes are linked to host immune responses and may be affected by antiviral therapy. We investigated antibody and cytokine responses in ACTT-1 study participants enrolled at our center. We studied serum specimens from 19 hospitalized adults with COVID-19 randomized to treatment with remdesivir or placebo. We assessed severe acute respiratory syndrome coronavirus 2 antibody responses and identified cytokine signatures, using hierarchical clustering. We identified no clear immunologic trends attributable to remdesivir treatment. Seven participants were initially seronegative at study enrollment, and all 4 deaths occurred in this group with more recent symptom onset. We identified 3 dominant cytokine signatures, demonstrating different disease trajectories.

Indexed as

Adenosine MonophosphateAdultAlanineAntibodies, ViralAntiviral AgentsCOVID-19COVID-19 Drug TreatmentCytokinesFemaleHumansImmunityMaleSARS-CoV-2Adenosine MonophosphateAlanineAntibodies, ViralAntiviral AgentsCytokinesremdesivirACTT-1COVID-19cytokineneutralizationremdesivirserologytrajectory

Identifiers

PMID33476387
PMCPMC7928927
OpenAlexW3123383499

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.